Lord, Abbett & Co. LLC Sage Therapeutics, Inc. Transaction History

Lord, Abbett & Co. LLC

$31.4 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Oct 07, 2024	BUY	$40.65 - $59.54 $25.9 Million - $37.9 Million	637,244 Added 334.8%	827,577 $38.9 Million
Q2 2023 Aug 14, 2023	BUY	$40.65 - $59.54 $25.9 Million - $37.9 Million	637,244 Added 334.8%	827,577 $38.9 Million
Q1 2023 Oct 07, 2024	BUY	$37.27 - $46.57 $7.09 Million - $8.86 Million	190,333 New	190,333 $7.99 Million
Q1 2023 May 12, 2023	BUY	$37.27 - $46.57 $7.09 Million - $8.86 Million	190,333 New	190,333 $7.99 Million
Q4 2019 Feb 14, 2020	SELL	$60.18 - $154.77 $13.4 Million - $34.4 Million	-221,994 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$140.29 - $189.96 $36 Million - $48.7 Million	-256,617 Reduced 53.62%	221,994 $31.1 Million
Q2 2019 Aug 14, 2019	SELL	$157.85 - $183.09 $22.4 Million - $26 Million	-142,057 Reduced 22.89%	478,611 $87.6 Million
Q1 2019 May 15, 2019	BUY	$89.33 - $163.65 $44 Million - $80.7 Million	492,910 Added 385.82%	620,668 $98.7 Million
Q4 2018 Feb 14, 2019	SELL	$81.94 - $139.71 $14.2 Million - $24.1 Million	-172,807 Reduced 57.49%	127,758 $12.2 Million
Q3 2018 Nov 14, 2018	SELL	$138.11 - $169.04 $33.2 Million - $40.6 Million	-240,313 Reduced 44.43%	300,565 $42.5 Million
Q2 2018 Aug 14, 2018	BUY	$140.36 - $175.76 $10.2 Million - $12.8 Million	73,024 Added 15.61%	540,878 $84.7 Million
Q1 2018 May 15, 2018	SELL	$152.15 - $192.33 $31 Million - $39.2 Million	-203,681 Reduced 30.33%	467,854 $75.4 Million
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $24 Million - $66.2 Million	395,870 Added 143.61%	671,535 $111 Million
Q3 2017 Nov 14, 2017	SELL	$61.4 - $88.52 $5.28 Million - $7.61 Million	-86,023 Reduced 23.78%	275,665 $17.2 Million
Q2 2017 Aug 14, 2017	BUY	N/A	361,688	361,688 $28.8 Million

Others Institutions Holding SAGE

# of Institutions

198

Shares Held

46.5M

Call Options Held

402K

Put Options Held

209K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.

Account